Contact - Gossamer Bio
USA Office3115 Merryfield RowSuite 120San Diego, CA 92121 Ireland Office77 Sir John Rogerson’s Quay, Block CGrand Canal DocklandsDublin 2, D02 VK60 Sponsorship …
Patients Overview - Gossamer Bio
If you are interested in receiving additional information about our clinical trials, please fill out the form on our Contact Page. Gossamer Bio’s Advocacy Partners
Home - Gossamer Bio
Sera lutinib. A breath of new promise. Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of …
FAQs - Gossamer Bio
How do I report a change of mailing address? If the shares are held in your name, you must contact Gossamer’s transfer agent, Computershare Limited. If your shares are held in street …
Gossamer Bio Announces Publication of TORREY Phase 2 Results …
May 3, 2024 · Contact IR Email Alerts Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine. May 3, 2024. PDF Version. SAN DIEGO- …
Gossamer Bio and Chiesi Group Announce Transformative Global ...
May 6, 2024 · - Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones - - …
Overview - Gossamer Bio
Aug 26, 2024 · Email Alerts Mission Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of …
Open Positions - Gossamer Bio
Notice to Search Firms/Third-Party Recruitment Agencies (Recruiters) The Human Resources team manages the recruitment and employment process for Gossamer Bio. To protect the …
News - Gossamer Bio
Jan 7, 2025 · Contact IR Email Alerts Year. January 7, 2025. Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) USA 3115 Merryfield Row Suite 120 …
About - Gossamer Bio
Ireland 77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands Dublin 2, D02 VK60